© EQS Newswire
04.11.2025
EVT
LISTED
XETR
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties
News Preview
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules
Transaction showcases Evotec’s unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing techn......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
EVT
LISTED
XETR
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen
News Preview
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen an einem Portfolio von bis zu 10 Biosimilar-Molekülen
Die Transaktion unterstreicht Evotecs einzigartige Fähigkeiten Kunden durch ihre kontinuierliche Produktionsstechn......
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
CYRX
LISTED
NASDAQ
Cryoport Reports Third Quarter 2025 Financial Results
News Preview
Third quarter revenue increased 15% year-over-year to $44.2 million
Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million
Life Sciences Service...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.11.2025
TEM
LISTED
NASDAQ
Tempus Reports Third Quarter 2025 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025.
Revenue grew 84.7% year-over-year to $334.2 million in the third quarter of 2025
Gross profit reached $209.9 million in the third quarter of 20...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
04.11.2025
EVT
LISTED
XETR
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
News Preview
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technologyAccelerated implementation of strategy through better monetization of technology and transitioning to an asset-lighter business modelAgreement includes approximately US$ 350 m in cash for...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
News Preview
CONSHOHOCKEN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides corporate updates....
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ILM1
LISTED
XETR
Montega AG: Medios AG | Rating: Kaufen
News Preview
Original-Research: Medios AG - von Montega AG
04.11.2025 / 11:41 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss......
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an a...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an a...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
04.11.2025
BAVA
LISTED
CPH
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
News Preview
COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
COLO B
LISTED
CPH
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
News Preview
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
COLO B
LISTED
CPH
Coloplast A/S - Full-Year Financial Results 2024/25
News Preview
2024/25Full year financial results...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
04.11.2025
AGL
LISTED
AIMX
Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding
News Preview
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of CTC testing into routine clinical practice within 5 yearsCTCs provide distinct and impactful information that is not captured by circulating tumour DNA (ctDNA)40% of the exp...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
KPTI
LISTED
NASDAQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted a...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
MNMD
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grant
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 90,750 common...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
UCB
LISTED
EURONEXT
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
News Preview
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.1
Survi...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces Third Quarter 2025 Financial Results and Updates 2025 Outlook
News Preview
MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 3...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
REC
LISTED
EURONEXT
Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
News Preview
Poster presentations at ASH highlight advances in the understanding and research of Castleman disease, cold agglutinin disease, B-cell lymphoma, and other hematologic conditions
BRIDGEWATER, N.J., Nov. 3, 2025 /PRNewswire/ -- Recordati Rare Diseases Inc. today a...
Themefolio
Profiler
Peergroup
© ActuNews
03.11.2025
OXUR
LISTED
EURONEXT
Oxurion beëindigt gesprekken over eerder aangekondigde preklinische overname en zet integratie voort van een strategische klinische speler
News Preview
Leuven, BELGIË, 3 november 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, maakt bekend dat het de gesprekken heeft beëindigd met betrekking tot de overwogene overname van een vennootschap gespecialiseerd in preklinische microbiologische diensten (zie persbericht...
Themefolio
Profiler
Peergroup
© ActuNews
03.11.2025
OXUR
LISTED
EURONEXT
Oxurion met fin aux discussions relatives à une transaction ciblée en préclinique annoncée précédemment et poursuit l'intégration d'un acteur clinique stratégique
News Preview
Louvain, BELGIQUE – 3 novembre 2025 – 18h00 – Oxurion NV (Euronext Bruxelles : OXUR), société de sous-traitance pharmaceutique basée à Louvain, annonce la fin des discussions relatives à l'acquisition projetée d'une société spécialisée dans les services...
Themefolio
Profiler
Peergroup
© ActuNews
03.11.2025
OXUR
LISTED
EURONEXT
Oxurion ends discussions regarding previously announced preclinical transaction and continues integration of a strategic clinical partner
News Preview
Leuven, BELGIUM, November 3, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the termination of discussions regarding the planned acquisition of a company specialized in preclinical microbiology services (see press release dated June 19, 2025 – link). Following a thor...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions
composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
LEGN
LISTED
NASDAQ
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
News Preview
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
News Preview
Autolus announced the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
GMAB
LISTED
CPH
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
News Preview
Media ReleaseCOPENHAGEN, Denmark; November 3, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
INDV
LISTED
NASDAQ
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
News Preview
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization
Adherence to SUBLOCADE was associated with lower rates of infectious disease compl...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
MNMD
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exerci...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
KPTI
LISTED
NASDAQ
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
News Preview
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –
– Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ORY
LISTED
BME
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
News Preview
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced that the first patient has been enrolled in RESTORE, its multi‑center, open‑label Phase Ib clinical trial of iadademstat in adults...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures
News Preview
Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a tranched convertible loan from Sound Bioventures.The investment supports continued clinical development of BT-101, a pioneering stem cell-based thera...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ILM1
LISTED
XETR
Thomas Meier becomes new CEO of Medios AG
News Preview
Press release
Thomas Meier becomes new CEO of Medios AG
Berlin, November 3, 2025 – The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer (CEO) of the Company. He succeeds Matthias Gaertner, who will remain in office un......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ILM1
LISTED
XETR
Thomas Meier wird neuer Vorstandsvorsitzender der Medios AG
News Preview
Pressemitteilung
Thomas Meier wird neuer Vorstandsvorsitzender der Medios AG
Berlin, 3. November 2025 – Der Aufsichtsrat der Medios AG hat Thomas Meier mit Wirkung zum 1. Februar 2026 als Mitglied des Vorstands bestellt und zum neuen Vorsitzenden des Vorstands (CEO) der Gesellschaft ernannt. Er folgt Matthias Gärtner, der bis zum 31. Dezember 2025......
Themefolio
Profiler
Peergroup
© Newsfile
03.11.2025
COPN
LISTED
SIX
Cosmo Receives CE Certification for ColonPRO EU - The Most Advanced AI Software Platform for Colonoscopy in Europe
News Preview
Dublin, Ireland--(Newsfile Corp. - November 3, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
IBAB
LISTED
EURONEXT
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
News Preview
Dosimetry portfolio strengthened with Medical Imaging QA and AI validation ...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2025
BAVA
LISTED
CPH
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
News Preview
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, announced yesterday, and the Public Preparedness business....
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2025
CRW
LISTED
AIMX
The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot
News Preview
With HRSA's approval of eight manufacturer rebate plans, hospitals enter the 60-day readiness period before the January 1, 2026, launch.
DEERFIELD BEACH, Fla., Oct. 31, 2025 /PRNewswire/ -- The Craneware Group convened leaders from 25 major U.S. health systems,...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
FAGR
LISTED
EURONEXT
Fagron’s share buy-back program: Weekly update
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 October 2025 – 6PM CET...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
BAVA
LISTED
CPH
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
News Preview
COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% of the shares and voting rights in Bavarian Nordic A/S as of October 27, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
BAVA
LISTED
CPH
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in Investor Conferences in November and December 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025:
Jefferies Global Healthcare Conference in London
Fireside Chat: Wednesday, November 19, 2025 at 8:30AM GMT
Location: London
Citi's 2025 Global Heal...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta
News Preview
STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial with the company’s cell therapy BT-101 targeting the rare bone disease Osteogenesis imperfecta. The new results comprise two-year follow-up...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
BAVA
LISTED
CPH
Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox
News Preview
COPENHAGEN, Denmark, October 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the award of a joint procurement contract by the European Commission, through the Health Emergency Preparedness and Response Authority (HERA), enabling the EU, its member states and additional European countries1 to purchase up to 8 million doses of the Company’...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
NKTR
LISTED
NASDAQ
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
News Preview
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London....
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
MNMD
LISTED
NASDAQ
MindMed to Report Q3 2025 Financial Results on November 6, 2025
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, November 6, 2025 to report financial results for the third quarter ended Septem...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions
composant le capital...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
CYRX
LISTED
NASDAQ
Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
News Preview
First Global Supply Chain Solutions Company to Achieve
ISO 21973
Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies
NASHVILLE, Tenn., Oct. 30, 2025 /PRNewswir...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ORY
LISTED
BME
ORYZON to Participate in Upcoming Events in November
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
BIOA B
LISTED
STO
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
News Preview
STOCKHOLM, Oct. 30, 2025 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
AMRX
LISTED
NASDAQ
Amneal Reports Third Quarter 2025 Financial Results
News Preview
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
News Preview
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene t...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
News Preview
Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene t...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
FYB
LISTED
XETR
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
News Preview
Press Release // October 30, 2025
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its Nine-Month Results 2025 on November 13, 2025. The Management Boar......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2025
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt
News Preview
Pressemitteilung // 30. Oktober 2025
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2025 ein und gibt Teilnahme an Investorenkonferenzen im 4. Quartal 2025 bekannt
Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) plant die Neunmonatszahlen 2025 am 13. November 2025 zu veröffentlichen. Der Vorstand wird di......
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
MNMD
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
MNMD
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase comm...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
HNSA
LISTED
STO
Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
News Preview
LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical Colleg...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
